CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL): stock profile, AI score and financials

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CRL at 43.7/100 on a composite quality score built from its SEC filings, placing it at rank #1,956 of 2,925 stocks — the bottom half of the AI-ranked universe. CRL scores in the top quartile across earnings quality (86.6). Areas of concern include profitability (21.4) and revenue growth (22.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 41.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reports quarterly revenue of $1.0B, net income of $-1.5M, an operating margin of 11.9%. Top institutional holders of CRL by reported 13-F value include FMR, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CRL trades on the NYSE exchange and files with the SEC under CIK 1100682. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. directly from SEC EDGAR.

Financials through the period ended Jun 27, 2026SEC EDGAR: CIK 1100682 →